X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.
Lead Product(s): Salicylic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Bridge Partners
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 23, 2021
Details:
ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.
Lead Product(s): ASX-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orange Grove Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
